Cancer Vaccine

Heat shock protein complex successfully treats subset of malignant melanoma patients

Published in Vaccine Weekly, January 1st, 2003

by Maria G. Essig, MS, ELS, senior medical writer - A small but significant percentage of patients with malignant melanoma experienced complete remission or stabilization of the disease after vaccination with autologous tumor-derived heat shock protein gp96-peptide complexes.

Filiberto Belli and colleagues working in Italy and the U.S. vaccinated 42 patients who had stage IV malignant melanoma with at least one cycle (four weekly injections) of a vaccine containing autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96). Twenty-one of the patients in whom no progression occurred received a second cycle consisting of four biweekly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-01-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry